The Technical Analyst
Kura Oncology Inc [KURA]
Exchange: NASDAQ Sector: Healthcare Industry: Biotechnology
Kura Oncology Inc Price, Forecast, Insider, Ratings, Fundamentals & Signals
Current Signal: BUY (auto-tracking)
3.42% $19.65
America/New_York / 26 apr 2024 @ 16:00
| FUNDAMENTALS | |
|---|---|
| MarketCap: | 1 496.09 mill |
| EPS: | -2.08 |
| P/E: | -9.45 |
| Earnings Date: | May 02, 2024 |
| SharesOutstanding: | 76.14 mill |
| Avg Daily Volume: | 1.144 mill |
| RATING 2024-04-26 |
|---|
| B- |
| Neutral |
| RATINGS | ||
|---|---|---|
| Rating CashFlow: | Neutral | |
| Return On Equity: | Strong Sell | |
| Return On Asset: | Sell | |
| DE: | Neutral | |
| P/E: | Sell | |
| Price To Book: | Buy |
| QUARTER GROWTHS | ||||||
|---|---|---|---|---|---|---|
| 3/22 | 4/22 | 1/23 | 2/23 | 3/23 | 4/23 | |
| Revenue | n/a | n/a | n/a | n/a | n/a | n/a |
| Gr.Profit | n/a | |||||
| Ebit | ||||||
| Asset | ||||||
| Debt |
| PE RATIO: COMPANY / SECTOR |
|---|
| 0.00x |
| Company: PE -9.45 | sector: PE -3.05 |
| PE RATIO: COMPANY / INDUSTRY |
|---|
| -1.61x |
| Company: PE -9.45 | industry: PE 5.88 |
| DISCOUNTED CASH FLOW VALUE |
|---|
|
$0.275 (-98.60%) $-19.38 |
| Date: 2024-04-26 |
| Expected Trading Range (DAY) |
|---|
|
$ 18.57 - 20.73 ( +/- 5.50%) |
| ATR Model: 14 days |
Insider Trading
| Date | Person | Action | Amount | type |
|---|---|---|---|---|
| 2024-01-29 | Doyle Thomas James | Sell | 594 | Common Stock |
| 2024-01-29 | Doyle Thomas James | Sell | 761 | Common Stock |
| 2024-01-29 | Doyle Thomas James | Sell | 963 | Common Stock |
| 2024-01-29 | Bair Teresa Brophy | Sell | 2 053 | Common Stock |
| 2024-01-29 | Ford Kathleen | Sell | 1 496 | Common Stock |
| INSIDER POWER |
|---|
| 42.04 |
| Last 95 transactions |
| Buy: 6 371 376 | Sell: 2 723 562 |
Forecast:
16:00 - $19.65
Live Trading Signals (every 1 min)
Forecast
1: 16:00 - $19.65
Forecast 2: 16:00 - $19.65
Forecast 3: 16:00 - $19.65
SCORE
10.00
Buy
10.00
Buy
Score Algorithm Version: 1.2C
Last version updated: Fri April 15th, 2022
Last version updated: Fri April 15th, 2022
| Indicator Signals | |
|---|---|
| RSI 21 | |
| SMA | |
| Trend | |
| Trend 2 | |
| Trend 3 | |
| MACD |
| Volume Signals | |
|---|---|
| Price | $19.65 (3.42% ) |
| Volume | 0.543 mill |
| Avg. Vol. | 1.144 mill |
| % of Avg. Vol | 47.48 % |
| Signal 1: | |
| Signal 2: |
Today
Last 12 Months
RSI
Last 10 Buy & Sell Signals For KURA
0 Signals | Accuracy: 0.00% | Accuracy Buy: 0.00% | Accuracy Sell: 0.00%
Avg return buy: 0.00 % | Avg return sell: 0.00 %
$1 invested is now $1.00 or 0.00% since Coming Soon
| Date | Signal | @ | Closed | % | Feb 8 - 15:34 | sell | $20.26 | N/A | Active |
|---|
KURA
Kura Oncology, Inc., a clinical-stage biopharmaceutical company, develops medicines for the treatment of cancer in the United States. The company's pipeline consists of small molecule product candidates that target cancer. Its lead product candidates are ziftomenib, a small molecule inhibitor of the menin-Lysine K-specific Methyltransferase 2A protein-protein interaction for the treatment of genetically defined subsets of acute leukemias, including acute myeloid leukemia and acute lymphoblastic leukemia; and tipifarnib, an orally bioavailable inhibitor of farnesyl transferase that is in Phase II clinical trials for the treatment of solid tumors and hematologic indications. The company has a clinical collaboration with Novartis to evaluate the combination of tipifarnib and alpelisib in patients with head and neck squamous cell carcinoma whose tumors have HRAS overexpression or PIK3CA mutation and/or amplification. Kura Oncology, Inc. was founded in 2014 and is headquartered in San Diego, California.
Latest Press Releases
2024-04-25 07:30:00 - Press Release
Kura Oncology To Report First Quarter 2024 Financial Results
San diego, april 25, 2024 (globe newswire) -- kura oncology, inc. (nasdaq: kura), a clinical-stage biopharmaceutical company committed to realizing the promise of precision medicines for the treatment of cancer, today announced that it will report first quarter 2024 financial results after the close of u.s. financial markets on thursday, may 2, 2024. kura's management will host a webcast and conference call at 4:30 p.m. et / 1:30 p.m. pt that day to discuss the financial results and provide a corporate update.
2024-04-22 07:30:00 - Press Release
Kura Oncology Receives Breakthrough Therapy Designation For Ziftomenib In Npm1-mutant Aml
– ziftomenib is the first investigational treatment to be granted breakthrough therapy designation for npm1-mutant aml – – registration-directed trial of ziftomenib in npm1-mutant aml on track to complete enrollment by mid-2024 – san diego, april 22, 2024 (globe newswire) -- kura oncology, inc. (nasdaq: kura), a clinical-stage biopharmaceutical company committed to realizing the promise of precision medicines for the treatment of cancer, today announced that its investigational drug, ziftomenib, has been granted breakthrough therapy designation (btd) by the u.s. food and drug administration (fda) for the treatment of patients with relapsed/refractory (r/r) npm1-mutant acute myeloid leukemia (aml)...
2024-04-10 07:30:00 - Press Release
Kura Oncology To Participate In Stifel Targeted Oncology Forum
San diego, april 10, 2024 (globe newswire) -- kura oncology, inc. (nasdaq: kura), a clinical-stage biopharmaceutical company committed to realizing the promise of precision medicines for the treatment of cancer, today announced its participation in stifel 2024 targeted oncology forum. troy wilson, ph.d., j.d., president and chief executive officer, is scheduled to participate in a virtual fireside chat at 11:30 a.m. et / 8:30 a.m. pt on april 17, 2024. a live audio webcast of the fireside chat will be available in the investors section of kura's website at www.kuraoncology.com, with an archived replay following the event.
2024-04-05 07:30:00 - Press Release
Kura Oncology Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
San diego, april 05, 2024 (globe newswire) -- kura oncology, inc. (the “company”) (nasdaq: kura), a clinical-stage biopharmaceutical company committed to realizing the promise of precision medicines for the treatment of cancer, today announced that on april 1, 2024, the compensation committee of the company's board of directors (the “compensation committee”) granted inducement awards consisting of nonstatutory stock options to purchase 49,500 shares of common stock to four (4) new employees under the company's 2023 inducement option plan. the compensation committee approved the stock options as an inducement material to such employees' employment in accordance with nasdaq listing rule 5635(c)(4).
2024-03-06 07:30:00 - Press Release
Kura Oncology Reports First Patient Dosed In Trial Of Ko-2806 Plus Cabozantinib In Renal Cell Carcinoma
– company anticipates dosing of ko-2806 in combination with adagrasib in krasg12c-mutant nsclc next quarter –
Latest News
2024-04-25 07:30:00 - GlobeNewsWire
Kura Oncology to Report First Quarter 2024 Financial Results
SAN DIEGO, April 25, 2024 (GLOBE NEWSWIRE) -- Kura Oncology, Inc. (Nasdaq: KURA), a clinical-stage biopharmaceutical company committed to realizing the promise of precision medicines for the treatment of cancer, today announced that it will report first quarter 2024 financial results after the close of U.S. financial markets on Thursday, May 2, 2024. Kura's management will host a webcast and conference call at 4:30 p.m. ET / 1:30 p.m. PT that day to discuss the financial results and provide a corporate update.
2024-02-22 07:30:00 - GlobeNewsWire
Kura Oncology to Participate in Three Upcoming Investor Conferences
SAN DIEGO, Feb. 22, 2024 (GLOBE NEWSWIRE) -- Kura Oncology, Inc. (NASDAQ: KURA), a clinical-stage biopharmaceutical company committed to realizing the promise of precision medicines for the treatment of cancer, today announced that Troy Wilson, Ph.D., J.D., President and Chief Executive Officer, is scheduled to participate in three upcoming investor conferences:
2024-02-20 07:30:00 - GlobeNewsWire
Kura Oncology to Report Fourth Quarter and Full Year 2023 Financial Results
SAN DIEGO, Feb. 20, 2024 (GLOBE NEWSWIRE) -- Kura Oncology, Inc. (Nasdaq: KURA), a clinical-stage biopharmaceutical company committed to realizing the promise of precision medicines for the treatment of cancer, today announced that it will report fourth quarter and full year 2023 financial results after the close of U.S. financial markets on Tuesday, February 27, 2024. Kura's management will host a webcast and conference call at 4:30 p.m. ET / 1:30 p.m. PT that day to discuss the financial results and provide a corporate update.
2024-01-30 08:41:38 - Invezz
Kura Oncology stock jumped another 20% on Tuesday: here's why
Kura Oncology Inc (NASDAQ: KURA) rallied close to 20% this morning after reporting positive preliminary data for a Phase 1 study of its Ziftomenib “in combination with standards of care”. Ziftomenib trial pushes Kura Oncology stock up The dose-escalation trial studied the combination in patients of acute myeloid leukemia.
2023-12-12 15:32:16 - Seeking Alpha
Kura Oncology: Riding The Menin Hype Wave In AML Therapy
Kura Oncology is an oncology-focused biotech developing targeted therapies for various forms of cancer with high unmet need. Their pipeline includes ziftomenib for AML, with promising phase 2 results and a potential data readout in 2024. They are also developing tipifarnib for HRAS-mutated HNSCC, with breakthrough therapy designation and positive response rates in early trials.
2023-10-30 07:30:00 - GlobeNewsWire
Kura Oncology to Participate in Three Upcoming Investor Conferences
SAN DIEGO, Oct. 30, 2023 (GLOBE NEWSWIRE) -- Kura Oncology, Inc. (Nasdaq: KURA), a clinical-stage biopharmaceutical company committed to realizing the promise of precision medicines for the treatment of cancer, today announced that Troy Wilson, Ph.D., J.D., President and Chief Executive Officer, is scheduled to participate in three upcoming investor conferences.
2023-10-26 16:05:00 - GlobeNewsWire
Kura Oncology to Report Third Quarter 2023 Financial Results
SAN DIEGO, Oct. 26, 2023 (GLOBE NEWSWIRE) -- Kura Oncology, Inc. (Nasdaq: KURA), a clinical-stage biopharmaceutical company committed to realizing the promise of precision medicines for the treatment of cancer, today announced that it will report third quarter 2023 financial results after the close of U.S. financial markets on Thursday, November 2, 2023. Kura's management will host a webcast and conference call at 4:30 p.m. ET / 1:30 p.m. PT that day to discuss the financial results and provide a corporate update.
2023-10-04 13:31:24 - Zacks Investment Research
What Makes Kura Oncology (KURA) a New Buy Stock
Kura Oncology (KURA) has been upgraded to a Zacks Rank #2 (Buy), reflecting growing optimism about the company's earnings prospects. This might drive the stock higher in the near term.
2023-09-25 04:40:22 - Seeking Alpha
Kura's Ziftomenib: The Swiss Army Knife In AML Therapy
Kura Oncology's lead candidate, ziftomenib, shows dual-functionality in treating NPM1-mutant AML and overcoming resistance mutations. Company's financials robust with $477M in liquid assets, offsetting a manageable monthly cash burn of $10.2M, providing a 46.8-month cash runway. Given the clinical promise of ziftomenib and strong financial footing, the stock presents an attractive risk-to-reward profile; "Buy" recommendation.
2023-08-06 10:41:02 - Seeking Alpha
Kura Oncology, Inc. (KURA) Q2 2023 Earnings Call Transcript
Kura Oncology, Inc. (NASDAQ:KURA ) Q2 2023 Earnings Conference Call August 3, 2023 4:30 PM ET Company Participants Pete De Spain - Senior Vice President, Investor Relations & Corporate Communications Troy Wilson - President & Chief Executive Officer Tom Doyle - Senior Vice President, Finance & Accounting Conference Call Participants Jonathan Chang - Leerink Partners Roger Song - Jefferies Peter Lawson - Barclays Li Watsek - Cantor Bijan Mekoba - Stifel Julian Harrison - BTIG Reni Benjamin - JMP Securities Operator Good afternoon, ladies and gentlemen, and welcome to the Q2 2023 Kura Oncology, Inc. Earnings Conference Call. At this time, all lines are in listen-only mode.